Avid Bioservices Inc (CDMO)

[RRdog]

Johnny,

Shan and King appear to be wrong because they never figured on 3 test subjects being dropped due to misnomering on type III and IV disease. It was an overstatement on their part and unnecessary. 86 subjects divided by two arms of study equals 43. 3/43 accounts almost precisely for the 7% overstatement.

The decision to use an additional radiographic scan technique that was not used for Avastin, for SOC C/P in 1st line NSCLC, nor in Doxy for SOC in 2nd line NSCLC appears to be a grievous self inflicted wound with very little upside. If MOS is what you need for movement at the FDA and in partnering why would we spend "company money" for a double trenche in testing on ORR and PFS???

The wound appears localized in the market cap number and will be healed and corrected over time IMO. Move on if you can. This kind of "stuff" happens. It is not central to the case.

Make yourself feel better by sending mgmt a copy of the Dart convertible funding for 40mm by ASTM.

Regards
RRdog